- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04797585
Vaginal Hysterectomy vs Supracervical Hysterectomy at the Time of Sacrocolpopexy (Coloplast LSC)
A Prospective Randomized Trial Comparing Vaginal Hysterectomy and Laparoscopic Supracervical Hysterectomy at the Time of Sacrocolpopexy for the Treatment of Uterovaginal Prolapse
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Procedures:
Study Identification and Recruitment Potential subjects will be identified by members of the Center for Urogynecology & Pelvic Reconstructive Surgery at the Cleveland Clinic Main campus, Hillcrest Hospital and Fairview Hospital. Eligible patients who agree to participate will be provided written informed consent administered by the collaborators listed on this IRB.
Randomization All subjects will be predetermined by their surgeon to undergo a laparoscopic sacrocolpopexy. The participants will then be randomized to either concurrent vaginal hysterectomy or laparoscopic supracervical hysterectomy according to a computer-generated randomization schedule with the use of the SAS statistical software package (SAS Institute, Cary, NC).
Office Interventions All patients will be seen for a preoperative visit and then postoperatively at 6, 12 and 24 months. The 6 month visit will be standard of care, the 12 month and 24 month visit will be a research visit. At each visit, a vaginal exam and a complete Pelvic Organ Prolapse Quantification (POP-Q) exam will be performed. In addition, patients will be asked to complete the Pelvic Floor Distress Inventory (PFDI-20), Incontinence Severity Index (ISI), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and Patient Global Impression of Improvement (PGII) questionnaires at the pre-operative visit as well as the 6, 12, and 24 month postoperative visits. Completion of these questionnaires is the only additional assessment that is specific to participation in this study and is not usually included as part of the standard care of sacrocolpopexy. It should take no more than 10-15 minutes to complete the questionnaires. The study subjects will not be exposed to any additional risk by participating in this study except for the inconvenience of completing the questionnaires.
Surgical Interventions The laparoscopic portions of the surgery will be performed using four ports: an umbilical port for the laparoscope (either 5 or 10/12mm), two ports (either 5, 8 or 10/12 mm) in the bilateral lower quadrants, and one 5-mm port placed at the level of the umbilicus, lateral to the rectus muscle on either side for retraction.
If a supracervical hysterectomy is to be performed, it will be done in a standard fashion. A uterine manipulator will be placed inside of the uterus. The round ligaments will be transected using cautery. The fallopian tubes and ovaries will be left in situ or removed at the time of hysterectomy depending upon the preoperative decision made between the surgeon and patient. The uterine arteries and cardinal ligaments will be cauterized laparoscopically. The uterus will be amputated at the level of the internal cervical os and the endocervical canal will be cauterized. The specimen will be extracted in a laparoscopic endocatch bag and removed through an extended incision at the umbilicus at the end of the case. Dissection of the vagina anteriorly and posteriorly will be done laparoscopically with the use of an end-to-end anastomosis (EEA) sizer in the vagina. Dissection of the presacral space will also be done laparoscopically. Five to six 2-0 PDS sutures will be placed to secure the mesh to the anterior vagina as well as the posterior vagina for a total of 10-12 sutures on the vagina; the arm of the mesh will be secured to the anterior longitudinal ligament of the sacrum using two 0 Prolene sutures. The Coloplast® Restorelle Y mesh will be used for all cases. The peritoneum will be closed with 0 or 2-0 vicryl sutures.
If a vaginal hysterectomy is performed, it will be done in a standard fashion using a traditional clamp and suture technique starting at the uterosacral ligaments and ending with the utero-ovarian ligaments. The specimen will be extracted through the vagina. Dissection of the vagina anteriorly and posteriorly will be done vaginally. The mesh will be attached vaginally using five to six 2-0 PDS sutures on the anterior and posterior vagina for a total of 10-12 sutures on the vagina. The Coloplast® Restorelle Dual flat mesh will be used. The vagina will then be closed in two layers using 0 or 2-0 vicryl suture. Laparoscopic entrance will then be gained and set up will be done as described above. The presacral space will be dissected laparoscopically and the mesh attached to the anterior longitudinal ligament of the sacrum using two 0 Prolene sutures. The peritoneum will be closed with 0 or 2-0 vicryl sutures.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cecile Ferrando, M.D.
- Phone Number: 216-444-0642
- Email: ferranc2@ccf.org
Study Contact Backup
- Name: Research Line
- Phone Number: 216-445-8090
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Research Line
- Phone Number: 216-445-8090
-
Contact:
- Cecile Ferrando, M.D.
- Phone Number: 216-444-0642
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18, who are to undergo laparoscopic sacrocolpopexy for uterovaginal prolapse and desire concurrent hysterectomy at the time of surgery
- Other concomitant laparoscopic or prolapse and anti-incontinence procedures (cystocele repair, rectocele repair or mid-urethral sling procedures) will be performed at the primary surgeon's discretion.
- Patient's must have an up-to-date PAP smear on record, or a PAP smear is performed in the office and verified to be normal pre-enrollment
Exclusion Criteria:
- Inability to comprehend written and/or spoken English
- Inability to provide informed consent
- Medical illness precluding laparoscopy
- Need for concomitant surgeries not related to pelvic organ prolapse or incontinence
- Sacrocolpoperineopexy
- Patients desiring uterine preservation (hysteropexy)
- Previous apical prolapse surgery (hysteropexy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Laparoscopic supracervical hysterectomy
Minimally invasive procedure to remove a woman's uterus
|
Laparoscopic supracervical hysterectomy
|
|
Experimental: Vaginal hysterectomy
Surgical procedure to remove the uterus
|
Vaginal hysterectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total surgical time - Time of incision to time of sacrocolpopexy completion
Time Frame: One day intraoperative
|
Completion = time of abdominal incisions closed
|
One day intraoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative mean difference PFDI-20 at 24 months
Time Frame: 24 months
|
Mean difference between baseline (pre-operative) and 24 months post-procedure.
The Pelvic Floor Disability Index (PFDI-20) is a is a short form that gives a comprehensive assessment of the effect of pelvic floor disorders.
The scale exists from 0-4 (0=not present, 4=quite a bit)
|
24 months
|
|
Post-operative mean difference ISI at 24 months
Time Frame: 24 months
|
Mean difference between baseline (pre-operative) and 24 months post-procedure.
The Incontinence Severity Index (ISI) consists of two questions, regarding frequency and amount of leakage.
It categorizes urinary incontinence (UI) into slight, moderate, severe, and very severe.
The scale exists from 0-12 (0=none, 12=very severe).
|
24 months
|
|
Post-operative mean difference PGII at 24 months
Time Frame: 24 months
|
Mean difference between baseline (pre-operative) and 24 months post-procedure.
The Patient Global Improvement Indices (PGII) is a seven-item measure which measures symptoms and degree of bother.
The scale exists from 0-7 (0=very much better, 7=very much worse).
|
24 months
|
|
Post-operative mean difference PISQ-12 at 24 months
Time Frame: 24 months
|
Mean difference between baseline (pre-operative) and 24 months post-procedure.
The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) is a validated and reliable short form that evaluates sexual function in women with urinary incontinence and/or pelvic organ prolapse.
The scale exists from 0-4 (0=never, 4=always).
|
24 months
|
|
Postoperative subjective recurrence at 24 months
Time Frame: 24 months
|
Subjective recurrence is defined as patients who complain of vaginal bulge sumptoms (Question #3 on the PFDI-20)
|
24 months
|
|
Reported mesh erosion at 24 months
Time Frame: 24 months
|
Mesh erosion is defined as presence of eroded mesh in the vagina on examination postoperatively up to 24 months after surgery
|
24 months
|
|
Postoperative objective recurrence at 24 months
Time Frame: 24 months
|
Objective recurrence is defined by POP-Q: Apical descent greater than one-third of total vaginal length or anterior or posterior vaginal wall beyond the hymen
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cecile Ferrando, M.D., The Cleveland Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 20-1293
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginal Hysterectomy
-
Ain Shams UniversityTerminated
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruiting
-
Mayo ClinicPacira Pharmaceuticals, IncTerminated
-
Southern HealthJohnson & JohnsonUnknownVaginal HysterectomyAustralia
-
Wolfson Medical CenterRecruiting
-
Wake Forest University Health SciencesCompleted
-
University of LouisvilleCompletedPhysical Activity | Surgery | Vaginal Hysterectomy | Vaginal SurgeryUnited States
-
Zuyderland Medisch CentrumCatharina Ziekenhuis EindhovenRecruitingHysterectomy | Natural Orifice Transluminal Endoscopic Surgery | Vaginal HysterectomyNetherlands
-
Heracure Medical Ltd.RecruitingVaginal or Laparoscopic HysterectomyIsrael
-
Hospices Civils de LyonCompletedLaparoscopy | Uterine Myomatosis | Hysterectomy, VaginalFrance
Clinical Trials on Laparoscopic supracervical hysterectomy
-
Medway NHS Foundation TrustJohnson & JohnsonUnknownBenign Disease of the UterusUnited Kingdom
-
Brigham and Women's HospitalWithdrawnGynecologic DiseasesUnited States
-
Oslo University HospitalUnknownDysmenorrhea | Total Laparoscopic Hysterectomy | Abnormal Uterine Bleeding | Laparoscopic Supracervical Hysterectomy | FibromasNorway
-
Ullevaal University HospitalUnknown
-
University Magna GraeciaJohnson & JohnsonCompleted
-
Kantonsspital AarauRecruitingUterus ProlapseSwitzerland
-
Brigham and Women's HospitalTerminatedUterine ProlapseUnited States
-
Atlantic Health SystemIntuitive SurgicalCompleted
-
Oslo University HospitalCompleted
-
University of PalermoNot yet recruiting